The PBAC may be unconcerned about some unimplemented recommendations but it could also 'remake' outcomes to make a listing possible, albeit after two years.
Could the 'review' process resolve disputes and not just rescind outcomes?
June 29, 2020 Latest News
Latest Video
New Stories
-
Vitex opens $250 million pharmaceutical manufacturing facility in Western Sydney
July 6, 2026 - - Latest News -
Early clinical imaging shows Syntara candidate reduces brain inflammation in people at high risk of Parkinson’s
July 6, 2026 - - Australian Biotech -
Widespread use of statins narrows heart-risk gap between overweight and normal-weight adults
July 6, 2026 - - Latest News -
A performative change that still leaves the door open for a response to 'MFN' risk
July 6, 2026 - - Latest News -
New law proposes limiting trade minister's power over PBS concessions
July 6, 2026 - - Latest News -
The 'Dispatched' Podcast - Season 5, Episode 22
July 3, 2026 - - Podcast -
Is that a subtle but meaningful shift conceding the potential need for a response to global realities?
July 3, 2026 -

